Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy, Inc. (NAUT)
:NAUT
RESEARCH TOOLSreports
NAUT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $3.09
Previous CloseN/A
Volume36.21K
Average Volume (3M)103.20K
Market Cap
$200.90M
Enterprise Value$248.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Feb 27, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding125,563,965
10 Day Avg. Volume96,298
30 Day Avg. Volume103,200
Standard Deviation0.15
R-Squared0.15
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.56
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$5.00Price Target Upside212.50% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
---
Nautilus Biotechnolgy News
PremiumCompany Announcements
Nautilus Biotechnology Announces Board Member Departures
PremiumCompany Announcements
Nautilus Biotechnology Reports Q3 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityPrudent cost management enables cash runway to extend into 2027.
Technology DevelopmentProgress towards developing a differentiated proteomics offering and continued cash management remains encouraging.
Bears Say
Commercial Launch DelaysTimelines for the commercial launch are extended and a late '25 to '26 launch is seen as more realistic.
---
Ownership Overview
42.95% Insiders
3.84% Mutual Funds
41.42% Other Institutional Investors
7.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAUT FAQ
What was Nautilus Biotechnolgy, Inc.’s price range in the past 12 months?
Nautilus Biotechnolgy, Inc. lowest stock price was $1.53 and its highest was $3.09 in the past 12 months.
What is Nautilus Biotechnolgy, Inc.’s market cap?
Nautilus Biotechnolgy, Inc.’s market cap is $200.90M.
When is Nautilus Biotechnolgy, Inc.’s upcoming earnings report date?
Nautilus Biotechnolgy, Inc.’s upcoming earnings report date is Feb 27, 2025 which is in 4 days.
How were Nautilus Biotechnolgy, Inc.’s earnings last quarter?
Nautilus Biotechnolgy, Inc. released its earnings results on Oct 29, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.035.
Is Nautilus Biotechnolgy, Inc. overvalued?
According to Wall Street analysts Nautilus Biotechnolgy, Inc.’s price is currently Undervalued.
Does Nautilus Biotechnolgy, Inc. pay dividends?
Nautilus Biotechnolgy, Inc. does not currently pay dividends.
What is Nautilus Biotechnolgy, Inc.’s EPS estimate?
Nautilus Biotechnolgy, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Nautilus Biotechnolgy, Inc. have?
Nautilus Biotechnolgy, Inc. has 125,563,965 shares outstanding.
What happened to Nautilus Biotechnolgy, Inc.’s price movement after its last earnings report?
Nautilus Biotechnolgy, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went down -1.423%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy, Inc.?
Currently, no hedge funds are holding shares in NAUT
---
Nautilus Biotechnolgy Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$5.00 (212.50% Upside)
$5.00 (212.50% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.40%
12-Months-Change
Fundamentals
Return on Equity
-28.04%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy, Inc.
ARYA Sciences Acquisition Corp III is a blank check company.
---
NAUT Company Deck
---
NAUT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in proteoform data and cash management, yet challenges remain in achieving broadscale discovery milestones and probe candidate performance. Plans for commercial launch in late 2025 are still on track.Read More>---
NAUT Stock 12 Month Forecast
Average Price Target
$5.00
▲(212.50% Upside)
Technical Analysis
Best Analysts Covering NAUT
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-29.30%
assigned a buy rating 4 months ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -29.30% per trade.
---